Biomarkers in community-acquired pneumonia: A state-of-the-art review

AUTOR(ES)

Seligman, Renato, Ramos-Lima, Luis Francisco, Oliveira, Vivian do Amaral, Sanvicente, Carina, Pacheco, Elyara F, Dalla Rosa, Karoline

FONTE

Clinics

DATA DE PUBLICAÇÃO

2012-11

RESUMO

Community-acquired pneumonia (CAP) exhibits mortality rates, between 20% and 50% in severe cases. Biomarkers are useful tools for searching for antibiotic therapy modifications and for CAP diagnosis, prognosis and follow-up treatment. This non-systematic state-of-the-art review presents the biological and clinical features of biomarkers in CAP patients, including procalcitonin, C-reactive protein, copeptin, pro-ANP (atrial natriuretic peptide), adrenomedullin, cortisol and D-dimers.

Documentos Relacionados

• Biomarkers in community-acquired pneumonia: can we do better by using them correctly?
• Community‐acquired pneumonia: doctors do not follow national guidelines
• Community-acquired pneumonia in adults.
• Use of a critical pathway for the management of community-acquired pneumonia: the CAPITAL study
• Aetiology of community-acquired pneumonia: a prospective study among adults requiring admission to hospital.